IGC Pharma (IGC) Finished Goods (2020 - 2026)

IGC Pharma (IGC) has reported Finished Goods for 7 consecutive years, with $191000.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Finished Goods fell 25.39% year-over-year to $191000.0 in Q1 2026; TTM through Mar 2026 was $191000.0, a 25.39% decrease from a year earlier, with the FY2026 full-year figure at $191000.0, down 25.39% from the prior year.
• Finished Goods was $191000.0 for Q1 2026 at IGC Pharma, down from $194000.0 in the prior quarter.
• Over five years, Finished Goods peaked at $801000.0 in Q3 2022 and troughed at $191000.0 in Q1 2026.
• A 5-year average of $458705.9 and a median of $441000.0 in 2024 frame the typical range for Finished Goods.
• Across the five-year window, Finished Goods decreased 17.26% in 2024 and sank 47.52% in 2025, its largest moves.
• Over 5 years, Finished Goods stood at $706000.0 in 2022, then fell by 27.62% to $511000.0 in 2023, then declined by 28.77% to $364000.0 in 2024, then sank by 46.7% to $194000.0 in 2025, then decreased by 1.55% to $191000.0 in 2026.
• The last three Finished Goods figures came in at $191000.0 (Q1 2026), $194000.0 (Q4 2025), and $212000.0 (Q3 2025), per Business Quant data.